{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.5","upperLimit":"27.6","value":"16.5"},{"groupId":"OG001","lowerLimit":"8.4","upperLimit":"16.7","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"OG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"OG001","title":"Arm II: ZLD"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"time from randomization to treatment failure (up to 5 years)","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}